| Biotech Co.* | Pharma Co. | Change from original agreement | Disclosed Funding (M) | Terms/Details |
| | ||||
I. MODIFIED AGREEMENTS | ||||
| Aclara | The R.W. | Extended collaboration providing early access to certain Aclara technologies for drug discovery | ND | RWJPRI and JRF will receive early access to Aclara's eTag assay technology (10/29) |
| Anadys Pharm- | Aventis Pharma | Extended collaboration to include Anadys' new assay development and screening platform | ND | The companies completed the initial three-year collaboration relating to the identification of novel fungal targets (10/9) |
| Icagen Inc.* | Bristol-Myers | Renewed research and development agreement for discovery and development of small-molecule drugs targeting a specific ion channel involved in atrial fibrillation | ND | The renewal provides for continued research and development funding by Bristol-Myers; the original deal, signed in 1997, was valued at up to $75M (10/22) |
| IDEC Pharma- | Mitsubishi | Broadened deal to develop the psoriasis monoclonal antibody IDEC-114 | $35 | Mitsubishi will help pay for clinical development of the drug and will conduct parallel clinical trials in Japan (10/19) |
| InterMune | Boeheringer | Expanded partnership to include the development and commercialization of interferon gamma-1b for the treatment of ovarian cancer | ND | Previous indications were idiopathic pulmonary fibrosis, tuberculosis, systemic fungal infections, chronic granulomatous disease and osteoporosis (10/16) |
| Kosan | The R.W. | Extended collaboration to Dec. 28, 2002, in which Kosan is producing novel macrolide antibiotic leads using its technology to genetically engineer microbial biosynthetic pathways | ND | The collaboration agreement was previously scheduled to terminate Dec. 28, 2001 (11/5) |
| Millennium | Bayer AG | Expanded $465M 1998 collaboration to include three additional indications | $465 | The collaboration will now include drug targets relevant to thrombosis, urinary incontinence and benign prostatic hypertrophy, in addition to cardiovascular disease, cancer, pain, hematology and viral infections; the companies discontinued efforts in osteoporosis and liver fibrosis (9/19) |
| ViroLogic Inc. | F. Hoffmann-La | Expanded agreement to use ViroLogic's HIV resistance testing technology | ND | The technology will be used in the development of T-20 and T-1249, members of a class of antiviral agents called fusion inhibitors (10/16) |
II. TERMINATED AGREEMENTS | ||||
| American | Abbott | Terminated rights | D | American Biogenetic reacquired the license rights for its neurological compound (11/12) |
| AtheroGenics | Schering- | Terminated rights | ND | AtheroGenics regained rights to AGI-1067 in order to more rapidly develop the compound (10/5) |
| CeNeS Pharm- | Bioglan Pharma | Terminated development and license agreement for a sublingual opiate spray | ND | CeNeS said it is terminating the agreement because Bioglan has failed to comply with its obligations (11/7**) |
| Chromos | Pharming | Termination of the research and license agreement | ND | Chromos completed a study required under the agreement to assess the feasibility of applying Chromos' Artificial Chromosome Expression System technology to the production of milk in transgenic animals (10/1) |
| Infigen Inc.* | Pharming | Terminated agreement to commercialize Infigen's transgenic technologies | ND | The termination also means Pharming and its subsidiaries must cease using intellectual property previously licensed by Infigen (10/15) |
| Neurochem | H. Lundbeck | Terminated partnership to develop a drug for Alzheimer's disease | $13 | The collaboration began in November 1999; Neurochem received about $13M from Lundbeck since the collaboration began (10/12) |
| Oxigene Inc. | Bristol-Myers | Terminated rights | ND | Bristol-Myers' strategic profile changed when several acquisitions were made; Oxigene regained rights to its agents (10/25) |
| Zonagen Inc. | Wyeth-Ayerst | Terminated option agreement | ND | Zonagen suspended further research on a zona pellucida-based contraceptive vaccine following inconsistent results from an ongoing baboon study (9/27) |
| | ||||
NOTES | ||||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. | ||||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the Nasdaq market. | ||||
| ** Denotes the date the item ran in BioWorld International. |
||||
| ND = Not disclosed, reported and/or available |
||||
| LSE = London Stock Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange |
||||
To read more on related topics, click on one of the words below.